YH25448, an irreversible EGFR-TKI with Potent Intracranial Activity in EGFR mutant non-small-cell lung cancer.

CONCLUSIONS: Our findings suggest that YH25448 is a promising third-generation EGFR inhibitor, which may be more effective and better tolerated than the currently approved osimertinib.
PMID: 30670498 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - January 22, 2019 Category: Cancer & Oncology Authors: Yun J, Hong MH, Kim SY, Park CW, Kim SY, Yun MR, Kang HN, Pyo KH, Lee SS, Koh JS, Song HJ, Kim DK, Lee YS, Oh SW, Choi S, Kim HR, Cho BC Tags: Clin Cancer Res Source Type: research